Thelansis’s "Chronic Hepatitis Delta Virus (HDV) Infection Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hepatitis Delta Virus (HDV) Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Chronic hepatitis D (HDV) is a severe viral liver disease that occurs only in people with hepatitis B virus (HBV), because HDV requires the HBV surface antigen to form infectious particles. It develops through simultaneous coinfection or superinfection of chronic HBV and can accelerate fibrosis, cirrhosis, liver failure and hepatocellular carcinoma. Diagnosis uses HDV antibody testing followed by HDV RNA to confirm active infection; fibrosis assessment and liver cancer surveillance are important. Pegylated interferon alfa was the main treatment for years, but limited response, adverse effects and relapse restricted its use. Bulevirtide (Hepcludex), an NTCP entry inhibitor, received accelerated FDA approval in May 2026 for adults without cirrhosis or with compensated cirrhosis. Other approaches in late-stage development include brelovitug, lonafarnib and tobevibart plus elebsiran. Durable viral control and proof of improved long-term liver outcomes remain key unmet needs.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Chronic Hepatitis Delta Virus (HDV) Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Chronic Hepatitis Delta Virus (HDV) Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.